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A femoral or iliac 
artery bruit in an 
asymptomatic 
patient warrants 
evaluation for 
peripheral artery 
disease with the 
ankle-arm index 
test.
  
How should you evaluate 
an asymptomatic patient with 
a femoral or iliac artery bruit?
Perform an ankle-arm index (AAI, or 
ankle-brachial index) test to evaluate for 
peripheral artery disease (PAD) (strength of 
recommendation [SOR]: B, cohort studies). 
If the test detects PAD, recommend steps 
to modify cardiovascular risk factors (SOR: 
B, extrapolation from randomized clinical 
trials [RCTs]). 
 Additional vascular diagnostic 
evaluation is not indicated, because no 
evidence suggests that proceeding with 
limb revascularization will improve outcomes 
in limb pain or function (SOR: C, expert 
opinion). Not enough evidence exists to 
recommend routine screening for iliac and 
femoral arterial bruits.
Evidence-based answer
❚ Evidence summary
PAD affects 7 million to 13 million Amer-
icans, or 3% to 18% of the population. 
Major risk factors include smoking, older 
age, hyperlipidemia, diabetes mellitus, 
obesity, cerebrovascular disease, coronary 
artery disease, hyperhomocysteinemia, 
and elevated C-reactive protein.1 PAD 
may cause claudication, ulcers, impo-
tence, or leg or thigh pain, although 20% 
to 50% of patients are asymptomatic.2 
Femoral artery bruit 
is better predictor of PAD
Further evaluation of an incidental iliac 
or femoral artery bruit helps assess the 
patient’s risk of arterial disease. Auscul-
tation of the femoral arteries for a bruit 
in asymptomatic patients is a moder-
ately good predictor of PAD (likelihood 
ratio [LR]=4.80; 95% confi dence inter-
val [CI], 2.40-9.50). The absence of a 
bruit doesn’t exclude disease, however 
(LR=0.83; 95% CI, 0.73-0.95).3 Auscul-
tation of an iliac artery bruit is a more 
modest predictor of disease (LR=2.2, no 
CI provided).4 
One study of 78 patients showed 
that a femoral or iliac artery bruit ac-
companied by either thigh claudication 
or an abnormal femoral pulse predicted 
PAD. Patients with 2 out of 3 of these 
clinical fi ndings had an 83% incidence 
of aortoiliac disease; the incidence was 
100% in patients with all 3 fi ndings.5 
Another study showed that bruits 
between the epigastrium and popliteal 
fossa were found in 63% of 309 patients 
with arterial disease, but only 7% of 149 
patients without PAD diagnosed by AAI 
or angiogram.6 
Follow up a bruit with AAI testing
Patients with femoral or iliac artery bruits 
should undergo AAI testing to assess the 
severity of disease. The AAI has 95% sen-
sitivity and almost 100% specifi city in 
identifying PAD, compared with angiogra-
phy.3 An AAI >0.90 is considered normal. 
An AAI of 0.71 to 0.90 indicates mild dis-
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ease, 0.41 to 0.70 indicates moderate dis-
ease, and ≤0.40 indicates severe disease.
Manage risk factors aggressively
Although no studies show specifi cally that 
modifying risk factors in a patient with 
asymptomatic PAD affects long-term 
outcomes, aggressive risk factor manage-
ment is recommended because PAD is 
highly associated with cerebrovascular 
and coronary artery disease.1 No data 
suggest that treating asymptomatic PAD 
improves future limb pain or function.
Recommendations
The American College of Cardiology/
American Heart Association 2005 Guide-
lines for the Management of Patients With 
Peripheral Arterial Disease2 make the fol-
lowing recommendations for patients with 
asymptomatic lower extremity PAD:
• Identify patients with asymptom-
atic lower extremity PAD by examination 
or by measuring the ankle-brachial index 
so therapeutic interventions known to 
reduce the risk of myocardial infarction, 
stroke, and death can be offered (level of 
evidence [LOE]: B).
• Address smoking cessation, lipid 
lowering, and diabetes and hypertension 
treatment according to national guide-
lines (LOE: B).
• Consider antiplatelet therapy to 
reduce the risk of adverse cardiovascular 
ischemic events (LOE: C).
The United States Preventive Ser-
vices Task Force recommends against 
routine screening for PAD (D recom-
mendation).7 ■
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The diagnosis and management of psychotic and mood disorders is an evolv-ing process and an important clinical topic for primary care clinicians (PCPs). 
Although many reports exist on the prevalence and treatment of depression in pri-
mary care, far less information is available about patients in this setting with depres-
sion accompanied by symptoms of mania or hypomania.1
To facilitate a dialogue on the identifi cation and treatment of psychotic and 
mood disorders, we invited 4 expert faculty members to present actual patient cases 
followed by a panel discussion in which the collective experience of all the faculty 
lends further practical insights into the nuances of management of such patients 
in both inpatient and outpatient settings. In particular, these cases underscore the 
importance of being alert to critical clues in a patient’s history or the family’s history. 
A larger version of this panel discussion appears in a supplement to the December 
2008 issue of CURRENT PSYCHIATRY. We’ve extracted the portion that we felt would be 
of most interest to primary care providers.
The case selected for presentation here is by David Muzina, MD, and concerns 
a 20-year-old man who was referred for psychiatric evaluation by his PCP and psy-
chologist for treatment of mood swings, anxiety, and confusion. He had been given 
sertraline and then venlafaxine, but discontinued both medications on his own. His 
symptoms began rather abruptly 14 months earlier, coinciding with an intense pro-
gram of weight lifting and supplement use to change his self-described smallness. 
Profound, persistent sadness and feeling “dead inside” were his chief complaints, 
and they had led to a break-up with his girlfriend, which distressed him greatly and 
preoccupied his thinking. He also believed his parents were hiding from him the 
truth of a signifi cant birth defect.
Following the case presentation is a faculty discussion of several pivotal issues 
in the management of mood disorders:
• Pitfalls to avoid during the diagnostic evaluation
• Pros and cons of monotherapy and combination therapy
•  Mechanisms of action of available medications and implications for an eff ec-
tive treatment plan
•  Suggestions for enabling patient compliance with prescribed regimens
We hope the insights you glean from this exchange of practical clinical issues 
will enhance and confi rm your own approach to diagnosing and treating patients 
with psychotic and mood disorders.
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